Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Hepion Pharmaceuticals Inc (HEPA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Hepion Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.370 +0.080    +6.20%
27/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 39,627
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.270 - 1.430
Hepion Pharmaceuticals 1.370 +0.080 +6.20%

Hepion Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Hepion Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

25

Equity Type

ORD

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Contact Information

Address 399 Thornall Street First Floor
Edison, 08837
United States
Phone 732 902 4000
Fax 732 902 4100

Top Executives

Name Age Since Title
Timothy M. Block 69 2013 Independent Director
Philippe Gallay - 2016 Member of Scientific Advisory Board
John Patrick Brancaccio 76 2013 Independent Chairman
Nikolai V. Naoumov - 2023 Member of Scientific Advisory Board
Kaouthar Lbiati 45 2022 Independent Director
Rohit Loomba - 2023 Member of Scientific Advisory Board
Yury V. Popov - 2023 Member of Scientific Advisory Board
Vlad Raziu - 2023 Member of Scientific Advisory Board
Stephen A. Harrison - 2019 Scientific Advisory Board Chair & Consultant Medical Director
Michael J. Purcell 66 2024 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HEPA Comments

Write your thoughts about Hepion Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email